A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in PregnancyPhysiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.
P2860
Q28088352-2D49BCF3-EBA8-43E3-9E7F-512CA83A38ADQ28307990-1B207F0B-A748-45B6-A209-15ECC1D06DABQ35211432-D0B2A44E-BF29-4873-BB47-3F2205696167Q35286070-F8CB7B1F-588D-4782-9A1C-BB3F908D2418Q35797203-25419BC5-06CA-4B84-BA4A-71FA827235D5Q36243626-DE3A3760-3EA9-4A19-B1E2-5C98D002E892Q36599597-9AF3894C-3C24-4E95-BE3D-AC7C0F426ED3Q36644907-6458DEE2-95FF-418C-80D5-E281E373CA8FQ36683248-57322FC6-2CF8-4BFF-B9F9-3E45290B02DFQ36706781-31178155-CD75-4D07-81C8-D60A6F7BB0CBQ37575742-F38C6311-0307-458E-A9C0-035561A1FF36Q38599220-FBEC58DC-63AD-4B98-8AAE-752B363BEAD0Q38661049-32BB50D5-E92E-4847-9A03-540F588DEEE0Q39247285-81FFFD2F-3AD3-4F88-A839-7A558F6E860FQ42713259-03D28130-62E0-43B3-B399-F4636D5C7D8AQ47387077-A87EEFB8-1E8C-4DC1-8660-5D0A62DB0757Q47724161-BF1DF73E-DDE2-445D-BA6E-C89F97123704Q47963328-197BF7FE-D7FE-43AC-804D-693FCBA7D92AQ47963518-6B56BD84-9554-40E5-BF1C-51E7A72E634EQ48072950-2EC3136E-0AAE-482B-B74C-B2FB3E884BAAQ50597914-6399F481-16CD-4B52-9AD1-761980DF164AQ50974898-7492FE54-C798-4109-A30B-E1406E2ACE16
P2860
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A physiologically based pharma ...... lized drugs in pregnant women.
@ast
A physiologically based pharma ...... lized drugs in pregnant women.
@en
type
label
A physiologically based pharma ...... lized drugs in pregnant women.
@ast
A physiologically based pharma ...... lized drugs in pregnant women.
@en
prefLabel
A physiologically based pharma ...... lized drugs in pregnant women.
@ast
A physiologically based pharma ...... lized drugs in pregnant women.
@en
P2093
P2860
P356
P1476
A physiologically based pharma ...... lized drugs in pregnant women.
@en
P2093
Alice Ban Ke
Amin Rostami-Hodjegan
Jashvant D Unadkat
Nina Isoherranen
Srikanth C Nallani
P2860
P304
P356
10.1124/DMD.112.050161
P577
2013-01-25T00:00:00Z